Indications and Purposes
| 1 Indications And Usage Soliris Is A Complement Inhibitor Indicated For: The Treatment Of Patients With Paroxysmal Nocturnal Hemoglobinuria (Pnh) To Reduce Hemolysis ( 1.1 ). The Treatment Of Patients With Atypical Hemolytic Uremic Syndrome (Ahus) To Inhibit Complement-Mediated Thrombotic Microangiopathy ( 1.2 ). Limitation Of Use Soliris Is Not Indicated For The Treatment Of Patients With Shiga Toxin E. Coli Related Hemolytic Uremic Syndrome (Stec-Hus). The Treatment Of Adult Patients With Generalized Myasthenia Gravis (Gmg) Who Are Anti-Acetylcholine Receptor (Achr) Antibody Positive ( 1.3 ). The Treatment Of Neuromyelitis Optica Spectrum Disorder (Nmosd) In Adult Patients Who Are Anti-Aquaporin-4 (Aqp4) Antibody Positive ( 1.4 ). 1.1 Paroxysmal Nocturnal Hemoglobinuria (Pnh) Soliris Is Indicated For The Treatment Of Patients With Paroxysmal Nocturnal Hemoglobinuria (Pnh) To Reduce Hemolysis. 1.2 Atypical Hemolytic Uremic Syndrome (Ahus) Soliris Is Indicated For The Treatment Of Patients With Atypical Hemolytic Uremic Syndrome (Ahus) To Inhibit Complement-Mediated Thrombotic Microangiopathy. Limitation Of Use Soliris Is Not Indicated For The Treatment Of Patients With Shiga Toxin E. Coli Related Hemolytic Uremic Syndrome (Stec-Hus). 1.3 Generalized Myasthenia Gravis (Gmg) Soliris Is Indicated For The Treatment Of Adult Patients With Generalized Myasthenia Gravis (Gmg) Who Are Anti-Acetylcholine Receptor (Achr) Antibody Positive. 1.4 Neuromyelitis Optica Spectrum Disorder (Nmosd) Soliris Is Indicated For The Treatment Of Neuromyelitis Optica Spectrum Disorder (Nmosd) In Adult Patients Who Are Anti-Aquaporin-4 (Aqp4) Antibody Positive. |
All Formulated Excipients (0 Total)
None
Active Ingredients ( 1 Total)
| Name | Structure | ZINC ID(s) |
|---|---|---|
| 1. Eculizumab |